Repare Therapeutics announced that it has made two additions to its leadership team and Board of Directors. Steve Forte is appointed as Executive Vice President & Chief Financial Officer and leads the Company's financial, capital markets and administrative operations. Samarth Kulkarni, PhD, CEO of CRISPR Therapeutics, has been appointed to Repare's Board of Directors as an independent director.

Steve is a senior financial leader who has managed in complex, large-scale healthcare financial environments. Until its recent sale to, he was CFO of Clementia Pharmaceuticals. Sam has served as CEO of CRISPR Therapeutics since 2017.

He has significant expertise in strategy and operations in biotechnology and a wide range of related cutting-edge therapeutic technologies. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer, and then served as President and Chief Business Officer.